2007
DOI: 10.1592/phco.27.10.1370
|View full text |Cite
|
Sign up to set email alerts
|

Mortality Reduction Benefits of a Comprehensive Cardiac Care Program for Patients with Occlusive Coronary Artery Disease

Abstract: Compared with those not enrolled in the CCC program, patients enrolled in the early CCC were 89% less likely to die. The earlier the program is started after a coronary event, the better the mortality reduction benefit.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
34
0

Year Published

2011
2011
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 37 publications
(34 citation statements)
references
References 35 publications
0
34
0
Order By: Relevance
“…Insurance products characterized as "others" are high deductible or triple option in our system; this association could reflect a particular patient-employer subset. At KPCO, antihyperlipidemic therapy is often instituted by a centralized pharmacist managed, physician monitored service, 32,33 and at primary care medical offices, clinical pharmacy specialists conduct lipid management. These services likely in part explain the association between prescribing by a non-primary care department and the antihyperlipidemic subgroup.…”
Section: Discussionmentioning
confidence: 99%
“…Insurance products characterized as "others" are high deductible or triple option in our system; this association could reflect a particular patient-employer subset. At KPCO, antihyperlipidemic therapy is often instituted by a centralized pharmacist managed, physician monitored service, 32,33 and at primary care medical offices, clinical pharmacy specialists conduct lipid management. These services likely in part explain the association between prescribing by a non-primary care department and the antihyperlipidemic subgroup.…”
Section: Discussionmentioning
confidence: 99%
“…4,5 The complexity of management, risks associated with inappropriate treatment, and high cost of ESA therapy make patients on these medications excellent candidates for pharmacist-based management. While anemia management services have demonstrated favorable impact on clinical and economic outcomes and patient satisfaction, [6][7][8][9][10][11] these have primarily used pre/post study designs, wherein the same patient population had its ESA therapy managed by a physician and then managed by a pharmacist and compared outcomes at different points in a patient's ESA therapy course.…”
Section: Patientsmentioning
confidence: 99%
“…At KPCO, a clinical pharmacy specialistmanaged service dedicated to patients with CAD has demonstrated improved outcomes for the patients enrolled and could be applied to patients with ischemic stroke. [29][30][31] Our study has some limitations. This was a retrospective, cross-sectional study; thus, temporal trends in the data were not assessed.…”
Section: Original Research and Contributions Ambulatory Treatment Gaps mentioning
confidence: 94%
“…Patients had to have either a validated NCIS or TIA between January 1, 2001, and December, 31,2009. Patients age 18 years or older with at least 1 inpatient stay or outpatient medical office visit with an International Classification of Diseases, Ninth Revision (ICD-9) diagnostic code between 430.xx and 438. xx and/or status code V12.54 (Personal History of Stroke) in the primary or secondary position recorded between January 1, 2001, and December 31, 2009, were identified administratively from inpatient hospital claims and outpatient visit records.…”
Section: Patient Populationmentioning
confidence: 99%